APA (7th ed.) Citation

DY, O., AR, H., S, Q., LT, C., T, O., JW, K., . . . JW, V. (2025). Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. Journal of hepatology, 83(5), 1092. https://doi.org/10.1016/j.jhep.2025.05.003

Chicago Style (17th ed.) Citation

DY, Oh, et al. "Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer: 3-year Overall Survival Update from the Phase III TOPAZ-1 Study." Journal of Hepatology 83, no. 5 (2025): 1092. https://doi.org/10.1016/j.jhep.2025.05.003.

MLA (9th ed.) Citation

DY, Oh, et al. "Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer: 3-year Overall Survival Update from the Phase III TOPAZ-1 Study." Journal of Hepatology, vol. 83, no. 5, 2025, p. 1092, https://doi.org/10.1016/j.jhep.2025.05.003.